NSE - Delayed Quote INR

Sakar Healthcare Limited (SAKAR.NS)

Compare
318.00 -3.95 (-1.23%)
At close: 3:29:13 PM GMT+5:30
Loading Chart for SAKAR.NS
DELL
  • Previous Close 321.95
  • Open 318.75
  • Bid --
  • Ask --
  • Day's Range 316.05 - 324.95
  • 52 Week Range 279.85 - 479.00
  • Volume 18,446
  • Avg. Volume 31,310
  • Market Cap (intraday) 6.916B
  • Beta (5Y Monthly) 0.39
  • PE Ratio (TTM) 53.36
  • EPS (TTM) 5.96
  • Earnings Date Feb 8, 2025 - Feb 12, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Sakar Healthcare Limited research, develops, manufactures, and markets pharmaceutical products in India. The company provides liquid orals, cephalosporin tablets, capsules, dry powder syrups, dry powder injections, liquid injectable (SVP) in ampoules, vials and lyophilized injections, and oral solid dosages. Its product portfolio consists of formulations in therapeutic areas, such as antacid, antimalerial, anticoagulant, laxative, anthelmintic, bronchodilator, anaesthetic, antidepressant, sedative, adrenergic, anti-infective, diuretics, oxytocic, analgesic, antiemetic, antipsychotic, antifungal, PPI, anticonvulsant, anti-inflammatory, antihistamine, and multi vitamins. The company exports its products to Southeast Asia, Asia, Africa-Anglo and Francophone, MENA countries, and the United States. Sakar Healthcare Limited was incorporated in 2004 and is based in Ahmedabad, India.

www.sakarhealthcare.com

325

Full Time Employees

March 31

Fiscal Year Ends

Recent News: SAKAR.NS

View More

Performance Overview: SAKAR.NS

Trailing total returns as of 12/12/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

SAKAR.NS
20.51%
S&P BSE SENSEX
12.53%

1-Year Return

SAKAR.NS
15.37%
S&P BSE SENSEX
16.25%

3-Year Return

SAKAR.NS
112.99%
S&P BSE SENSEX
38.28%

5-Year Return

SAKAR.NS
489.98%
S&P BSE SENSEX
101.15%

Compare To: SAKAR.NS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: SAKAR.NS

View More

Valuation Measures

Annual
As of 12/11/2024
  • Market Cap

    7.00B

  • Enterprise Value

    7.74B

  • Trailing P/E

    54.05

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.26

  • Price/Book (mrq)

    2.60

  • Enterprise Value/Revenue

    4.71

  • Enterprise Value/EBITDA

    17.93

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    7.52%

  • Return on Assets (ttm)

    3.90%

  • Return on Equity (ttm)

    4.90%

  • Revenue (ttm)

    1.65B

  • Net Income Avi to Common (ttm)

    124.03M

  • Diluted EPS (ttm)

    5.96

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.27M

  • Total Debt/Equity (mrq)

    31.13%

  • Levered Free Cash Flow (ttm)

    -418.3M

Research Analysis: SAKAR.NS

View More

Company Insights: SAKAR.NS

Research Reports: SAKAR.NS

View More

People Also Watch